DUBLIN--(BUSINESS WIRE)--The "Fragile X Syndrome - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Fragile X Syndrome - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 5, 2, 14, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Fragile X Syndrome - Overview
- Fragile X Syndrome - Therapeutics Development
- Fragile X Syndrome - Therapeutics Assessment
- Fragile X Syndrome - Companies Involved in Therapeutics Development
- Fragile X Syndrome - Drug Profiles
- Fragile X Syndrome - Dormant Projects
- Fragile X Syndrome - Discontinued Products
- Fragile X Syndrome - Product Development Milestones
- Appendix
Companies Mentioned
- Aelis Farma SAS
- Anavex Life Sciences Corp
- Confluence Pharmaceuticals LLC
- DRI Biosciences Corp
- Eli Lilly and Co
- Epigen Biosciences Inc
- Fulcrum Therapeutics Inc
- GlaxoSmithKline Plc
- GW Pharmaceuticals Plc
- Healx Ltd
- Marinus Pharmaceuticals Inc
- NeuCyte Inc
- Neuren Pharmaceuticals Ltd
- Neuron Biopharma SA
- Novartis AG
- Ovid Therapeutics Inc
- Sage Therapeutics Inc
- Sentinel Oncology Ltd
- Tetra Discovery Partners LLC
- Zynerba Pharmaceuticals Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/bgxhk7/fragile_x?w=4
